STEM-MYO: Targeting Muscle Atrophy

Preclinical data in aged moused models and preliminary Phase 1/2a clinical data in elderly adults suggests that IMM01-STEM can benefit older adults with muscle atrophy associated with knee osteoarthritis.

 

IMM01-STEM improves muscle mass, size, and strength while enhancing muscle tissue remodeling in aged mouse models

Immunis published preclinical research in GeroScience supporting that the investigational multi-active biologic (IMM01-STEM) improved muscle mass and strength during disuse and recovery in aged mouse models. 

Aged mice received intramuscular injections of IMM01-STEM during three experimental conditions: mobile mice (ambulatory controls), mice without use of hind leg muscles (disuse atrophy group), or mice recovering from disuse atrophy. Compared to control-treated, aged mice, IMM01-STEM treatment resulted in greater muscle mass, increased muscle fiber area, and improved grip strength for all three experimental conditions. There was also a decrease in collagen content and an increase in the number of muscle stem cells, indicative of an enhanced muscle remodeling response. Additionally, administration of IMM01-STEM to rodent muscle cell cultures increased muscle size and enhanced muscle regeneration.

Collectively, these preclinical findings demonstrate that Immunis’ novel therapy has immune modulatory effects that enhance muscle size and strength following atrophy. 

Read the publication or check out the video below for results from our GeroScience publication.

Read here

Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secretome product derived from partially differentiated human pluripotent stem cells

Fix, Dennis K., Ziad S. Mahmassani, Jonathan J. Petrocelli, Naomi M.M.P. de Hart, Patrick J. Ferrara, Jessie S. Painter, Gabriel Nistor, Thomas E. Lane, Hans S. Keirstead, and Micah J. Drummond. “Reversal of Deficits in Aged Skeletal Muscle during Disuse and Recovery in Response to Treatment with a Secrotome Product Derived from Partially Differentiated Human Pluripotent Stem Cells.” GeroScience 43, no. 6 (December 1, 2021): 2635–52. https://doi.org/10.1007/s11357-021-00423-0.

Phase 1/2a clinical trial investigates IMM01-STEM on muscle atrophy in patients with knee osteoarthritis (KOA)

A Phase 1/2a clinical trial measured the safety, tolerability, and preliminary efficacy of Immunis’ multi-active biologic in people with sarcopenia associated with KOA. The data are still under analysis, but thus far, there have been no serious adverse events attributable to IMM01-STEM, with a strong suggestion of enhanced muscle function.